Compare TTWO & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTWO | ALNY |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1B | 39.0B |
| IPO Year | 1999 | 2004 |
| Metric | TTWO | ALNY |
|---|---|---|
| Price | $229.42 | $281.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 28 |
| Target Price | $283.69 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 2.4M | 928.1K |
| Earning Date | 05-15-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 93.67 | ★ 206.88 |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $6,656,400,000.00 | $1,037,418,000.00 |
| Revenue This Year | $20.51 | $52.67 |
| Revenue Next Year | $36.62 | $31.48 |
| P/E Ratio | ★ N/A | $123.52 |
| Revenue Growth | 18.16 | ★ 22.88 |
| 52 Week Low | $187.63 | $281.36 |
| 52 Week High | $264.79 | $495.55 |
| Indicator | TTWO | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 40.89 |
| Support Level | $188.14 | N/A |
| Resistance Level | $248.72 | $314.04 |
| Average True Range (ATR) | 6.80 | 10.49 |
| MACD | -0.20 | -0.92 |
| Stochastic Oscillator | 86.69 | 15.94 |
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.